The approval allows Genzyme to begin returning patients to full doses of Fabrazyme. By March, patients in the U.S. will be returned to full dosing. Normal supply levels are expected by the second quarter.
Related Articles on the Supply Chain:
FDA Clears Medtronic’s Aquamantys SBS 5.0 Sheathed Bipolar Sealer for Spine Surgery
MScore Technology Assesses Surgeon Competency With da Vinci Robot
FDA, Life Sciences Trade Group Partner to Improve Medical Device Review
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
